Heejung Koo will attend at the PMWC 2018 Silicon Valley and present at the AI company showcase .

Standigm announced today that it has launched two AI-driven drug discovery services, Expander and Hunter. Expander is a service that new and better indications for customer’s in-house compounds. By using Expander service, pharmaceutical companies are now able to achieve a quick identification of a novel clinical use for their existing drugs with low cost and effort. Hunter, another service other than Expander, discovers repositioned lead compounds tailored to customer’s interest. Hunter is based on Standigm’s state-of-the-art AI technology and searches for potential drugs, protein targets to combat the specific diseases that our customers are interested in.  .

Jinhan Kim, Standigm CEO will speak at the Bio-Europe 2017 on November 7, 2017. Sang Ok Song, Standigm COO will also attend the meeting. Meet them in Berlin.

Standigm and Korea institute of science and technology (KIST) announced a research collaboration to develop a new small molecule medicine for Autism. The drug candidates chosen by Standigm’s AI drug discovery technology will validate experimentally by using KIST’s animal models.

CrystalGenomics, Inc., Standigm’s partner company, today announced a drug predicted by Standigm’s artificial intelligence technology showed the evidence that it may reuse for cancer treatment. The drug is an FDA-proved drug for other therapeutic uses. It has been only three months to sign the partnership between Standigm, Inc. and CrystalGenomics, Inc.